Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Emord takes on FDA over supplement GMPs

This article was originally published in The Tan Sheet

Executive Summary

The final rule for dietary supplement good manufacturing practices is "poorly written and unnecessarily a trap for the unwary," asserts attorney Jonathan Emord in a 1complaint filed Aug. 7 against FDA. The GMPs violate the Dietary Supplement Health and Education Act by allowing the agency to hold products as adulterated without proving they present a public health risk, he says. Emord also claims that because firms are not given proper guidance for complying with GMPs, the rule violates the constitutional prohibition against vague laws. Like his July 30 suit regarding FDA's rejection of health claims, the Aug. 7 suit also was filed in the U.S. District Court for the District of Columbia and on behalf of the Alliance for Natural Health U.S., the Coalition to End FDA and FTC Censorship and supplement businesspersons Durk Pearson and Sandy Shaw (2"The Tan Sheet" Aug. 3, 2009, In Brief)

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS103206

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel